G1 Therapeutics (GTHX) CEO Mark Velleca on Q3 2018 Results - Earnings Call Transcript [Seeking Alpha]
G1 Therapeutics, Inc. (GTHX)
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
g1therapeutics.com/pages/investors/investors.htm
Company Research
Source: Seeking Alpha
G1 Therapeutics (NASDAQ: GTHX ) Q3 2018 Earnings Conference Call November 7, 2018 4:30 PM ET Executives Jeff Macdonald - Head, IR & Public Relations Mark Velleca - President & CEO Barclay Phillips - CFO & SVP of Corporate Development & Secretary Rajesh Malik - Chief Medical Officer & SVP, R&D Analysts Tessa Romero - JP Morgan Chase David Nierengarten - Wedbush Securities Chad Messer - Needham & Company Edward White - H.C. Wainwright & Company Operator Good day, ladies and gentlemen, and welcome to the G1 Therapeutics Third Quarter 2018 Financial Results Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the call over to Jeff Macdonald. You may begin. Jeff Macdonald Thank you, operator. Good afternoon, everyone, and welcome to the G1 Therapeutics Third Quarter 2018 Financial Results and Corporate Update. Joining me are Mark Velleca, Chief Executive Officer; Raj Malik, Chief Medical Officer and Seni
Show less
Read more
Impact Snapshot
Event Time:
GTHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GTHX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GTHX alerts
High impacting G1 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GTHX
News
- Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape [Seeking Alpha]Seeking Alpha
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock, up previously from $4.00.MarketBeat
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.MarketBeat
GTHX
Earnings
- 2/28/24 - Beat
GTHX
Sec Filings
- 3/22/24 - Form 8-K
- 3/22/24 - Form 4
- 3/22/24 - Form 4
- GTHX's page on the SEC website